latest news Appendix 4C Third Quarter Report Appendix 3Y John Brown Target market expands for BioDiem's flu vaccine Half Yearly Accounts Appendix 3B Boardroomradio interview with Dr Andrew O'Brien Results of AGM CEO AGM Presentation Chairman's Address to Shareholders BioDiem receives 5th Milestone of US$1m for flu vaccine Notice of Meeting / Proxy Form 2007 Annual Report 2007 Investor Update October 2007 AusBiotech Forum Presentation Retirement of non-executive Director, Professor Robert Borland Appendix 4C Quarterly Report Open Briefing 'Equity Placement and Clinical Trial Results' Boardroomradio Interview with Andrew O'Brien Appendix 3B $7m raised in placement BDM-E clinical trial results Full Statutory Accounts Lodgement of Financial Statements and Reports Open Letter to Shareholders Final Director's Interest Notice BioDiem Board Changes BioDiem starts four new Monash studies with BDM-E Preliminary Final Announcement Commentary on Results June 30 2007 Boardroomradio interview with Tom Williams Treatment complete in phase I/II study of eye drug BDM-E Appendix 4C Quarterly Report Open Briefing 'Implications of Eye Peptide Studies' BDM-E repairs retinal damage in mice LAIV data presented at Options VI Conference in Canada Appendix 3B Russians trial new way of making pandemic flu vaccine Recruitment completed for BDM-E clinical trial New Patent filed for BDM-E 4th Milestone of US$1m received for flu vaccine | Investor InformationASX Announcements Financial Results
| ASX Link
|